SG11202002532XA - Novel anti-hla-a2 antibodies and uses thereof - Google Patents

Novel anti-hla-a2 antibodies and uses thereof

Info

Publication number: SG11202002532XA
Authority: SG; Singapore
Prior art keywords: hla; antibodies; novel anti; novel
Prior art date: 2017-09-20

Application number

SG11202002532XA

Inventor

Li Zhou

Tobias Abel

François Meyer

Megan Levings

Nicolas Dawson

Caroline Lamarche

Original Assignee

Univ British Columbia

Sangamo Therapeutics France

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-20

Filing date

2018-09-20

Publication date

2020-04-29

2018-09-20 Application filed by Univ British Columbia, Sangamo Therapeutics France filed Critical Univ British Columbia

2020-04-29 Publication of SG11202002532XA publication Critical patent/SG11202002532XA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Transplantation (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11202002532XA 2017-09-20 2018-09-20 Novel anti-hla-a2 antibodies and uses thereof SG11202002532XA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762560841P	2017-09-20	2017-09-20
US201862691027P	2018-06-28	2018-06-28
PCT/CA2018/051174 WO2019056106A1 (en)	2017-09-20	2018-09-20	Novel anti-hla-a2 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SG11202002532XA true SG11202002532XA (en)	2020-04-29

Family

ID=65810548

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202002532XA SG11202002532XA (en)	2017-09-20	2018-09-20	Novel anti-hla-a2 antibodies and uses thereof

Country Status (12)

Country	Link
US (2)	US11814432B2 (en)
EP (1)	EP3684822A4 (en)
JP (1)	JP7317023B2 (en)
KR (1)	KR20200090151A (en)
CN (1)	CN111448216B (en)
AU (1)	AU2018338423A1 (en)
BR (1)	BR112020005519A2 (en)
CA (1)	CA3076547A1 (en)
IL (1)	IL273401A (en)
MX (1)	MX2020003047A (en)
SG (1)	SG11202002532XA (en)
WO (1)	WO2019056106A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3058425A1 (en)	2017-03-28	2018-10-04	The Trustees Of The University Of Pennsylvania	Methods to protect transplanted tissue from rejection
CA3076261A1 (en)	2017-09-19	2019-03-28	The University Of British Columbia	Anti-hla-a2 antibodies and methods of using the same
EP3997212A4 (en) *	2019-07-09	2024-01-17	The Children's Mercy Hospital	Engineered regulatory t cells
WO2021034689A1 (en) *	2019-08-16	2021-02-25	H. Lee Moffitt Cancer Center And Research Institute Inc.	Anti-cd83 chimeric antigen receptor expressing t regulatory cells
CN112852748B (en) *	2020-04-16	2023-11-21	成都仕康美生物科技有限公司	Chimeric antigen receptor targeting HLA-A, coding gene, CAR-Tregs cell, preparation method and application thereof
CN111440246B (en) *	2020-04-16	2022-03-18	成都仕康美生物科技有限公司	Chimeric antigen receptor targeting HLA-B, encoding gene, CAR-Tregs cell and preparation method and application thereof
WO2023156587A1 (en) *	2022-02-18	2023-08-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
CN114316056A (en) *	2022-03-02	2022-04-12	天津一瑞生物科技股份有限公司	Mouse NDM (Newcastle disease virus) -resistant carbapenemase hybridoma cell strain, monoclonal antibody and application
WO2023172077A1 (en) *	2022-03-08	2023-09-14	주식회사 박셀바이오	Pd-l1-specific chimeric antigen receptor and immune cell comprising same

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
ES2241710T3 (en)	1991-11-25	2005-11-01	Enzon, Inc.	PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
WO1998056915A2 (en)	1997-06-12	1998-12-17	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
JP2003516124A (en)	1999-10-15	2003-05-13	ユニバーシティーオブマサチューセッツ	RNA interference pathway genes as a means of targeted genetic interference
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6905874B2 (en)	2000-02-24	2005-06-14	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
ES2528794T3 (en)	2000-04-11	2015-02-12	Genentech, Inc.	Multivalent antibodies and uses thereof
AU2001275474A1 (en)	2000-06-12	2001-12-24	Akkadix Corporation	Materials and methods for the control of nematodes
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2004233315A1 (en)	2003-04-24	2004-11-04	Fondazione Centro San Raffaele Del Monte Tabor	Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
AU2005250408B2 (en)	2004-05-27	2010-09-23	The Trustees Of The University Of Pennsylvania	Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1795599A1 (en)	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells
GB0603081D0 (en)	2006-02-15	2006-03-29	Dynal Biotech Asa Oslo	Method
TWI507204B (en)	2009-05-26	2015-11-11	Oncotherapy Science Inc	Cdc45l peptides and vaccines including the same
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
GB0919751D0 (en)	2009-11-11	2009-12-30	King S College Hospital Nhs Fo	Conjugate molecule
US8945868B2 (en)	2010-07-21	2015-02-03	Sangamo Biosciences, Inc.	Methods and compositions for modification of a HLA locus
SG190997A1 (en)	2010-12-09	2013-07-31	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
PL2694549T3 (en)	2011-04-08	2019-01-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
TR201806812T4 (en)	2012-05-25	2018-06-21	Charpentier Emmanuelle	Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modification.
JP2015180607A (en)	2012-08-01	2015-10-15	国立大学法人東京大学	Antibody which can treat disease associated with hematopoietic stem cell transplantation such as graft-versus-host disease, and functional fragment thereof and pharmaceutical composition comprising the same
JP2016505256A (en)	2012-12-12	2016-02-25	ザ・ブロード・インスティテュート・インコーポレイテッ	CRISPR-Cas component system, method and composition for sequence manipulation
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
CA2894684A1 (en)	2012-12-12	2014-06-19	The Broad Institute, Inc.	Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
CN103739667B (en) *	2013-09-24	2017-08-25	上海宇研生物技术有限公司	Special tumor antigen peptide of oophoroma and preparation method thereof
EP3263595A1 (en)	2016-06-30	2018-01-03	Medizinische Hochschule Hannover	Fusion protein for use in the treatment of hvg disease
CA3058425A1 (en)	2017-03-28	2018-10-04	The Trustees Of The University Of Pennsylvania	Methods to protect transplanted tissue from rejection
CA3076261A1 (en) *	2017-09-19	2019-03-28	The University Of British Columbia	Anti-hla-a2 antibodies and methods of using the same

2018
- 2018-09-20 SG SG11202002532XA patent/SG11202002532XA/en unknown
- 2018-09-20 KR KR1020207011261A patent/KR20200090151A/en active IP Right Grant
- 2018-09-20 CA CA3076547A patent/CA3076547A1/en active Pending
- 2018-09-20 MX MX2020003047A patent/MX2020003047A/en unknown
- 2018-09-20 EP EP18859115.0A patent/EP3684822A4/en active Pending
- 2018-09-20 US US16/649,426 patent/US11814432B2/en active Active
- 2018-09-20 BR BR112020005519-0A patent/BR112020005519A2/en unknown
- 2018-09-20 WO PCT/CA2018/051174 patent/WO2019056106A1/en unknown
- 2018-09-20 JP JP2020537814A patent/JP7317023B2/en active Active
- 2018-09-20 AU AU2018338423A patent/AU2018338423A1/en active Pending
- 2018-09-20 CN CN201880074978.9A patent/CN111448216B/en active Active
2020
- 2020-03-18 IL IL273401A patent/IL273401A/en unknown
2023
- 2023-09-27 US US18/475,582 patent/US20240067732A1/en active Pending

Also Published As

Publication number	Publication date
MX2020003047A (en)	2020-10-22
US20200283530A1 (en)	2020-09-10
US20240067732A1 (en)	2024-02-29
CA3076547A1 (en)	2019-03-28
RU2020112262A3 (en)	2022-02-22
RU2020112262A (en)	2021-10-25
EP3684822A1 (en)	2020-07-29
IL273401A (en)	2020-05-31
CN111448216B (en)	2023-11-07
JP7317023B2 (en)	2023-07-28
US11814432B2 (en)	2023-11-14
KR20200090151A (en)	2020-07-28
CN111448216A (en)	2020-07-24
BR112020005519A2 (en)	2020-10-27
JP2020535843A (en)	2020-12-10
AU2018338423A1 (en)	2020-04-09
EP3684822A4 (en)	2021-06-16
WO2019056106A1 (en)	2019-03-28

Publication	Publication Date	Title
IL290842A (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
ZA202102905B (en)	2023-04-26	Anti-galectin-9 antibodies and uses thereof
IL271901A (en)	2020-02-27	Anti-cd8 antibodies and uses thereof
ZA202101318B (en)	2023-03-29	Anti-phf-tau antibodies and uses thereof
IL272183A (en)	2020-03-31	Anti-cd8 antibodies and uses thereof
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and uses thereof
IL276950A (en)	2020-10-29	Anti-cd73 antibodies and uses thereof
IL266738A (en)	2019-07-31	Novel antibodies and uses thereof
IL282968A (en)	2021-06-30	Anti-nkg2a antibodies and uses thereof
IL273402A (en)	2020-05-31	Anti-hla-a2 antibodies and methods of using the same
IL269134A (en)	2019-11-28	Anti-par2 antibodies and uses thereof
IL273401A (en)	2020-05-31	Novel anti-hla-a2 antibodies and uses thereof
IL275826A (en)	2020-08-31	Anti-mct1 antibodies and uses thereof
IL272476A (en)	2020-03-31	Anti-apelin antibodies and uses thereof
IL281297A (en)	2021-04-29	Anti-npr1 antibodies and uses thereof
IL273157A (en)	2020-04-30	Axl-specific antibodies and uses thereof
IL271398A (en)	2020-01-30	Anti-l1-cam antibodies and uses thereof
IL283875A (en)	2021-07-29	Anti-il-27 antibodies and uses thereof
IL277330A (en)	2020-10-29	Anti-il-27 antibodies and uses thereof
IL281202A (en)	2021-04-29	Anti-tnfrsf9 antibodies and uses thereof
IL280321A (en)	2021-03-01	Anti-cxcr2 antibodies and uses thereof
IL277075A (en)	2020-10-29	Anti-phf-tau antibodies and uses thereof
IL276548A (en)	2020-09-30	Bcma-binding antibodies and uses thereof
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof